Relypsa, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$10.1M
Doctors Paid
13,986
Transactions
72,175
2020 Total
$980,819
Payment Breakdown by Category
Research$2.0M (19.9%)
Consulting$1.7M (16.8%)
Food & Beverage$1.6M (15.9%)
Travel$1.1M (10.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.4M | 1,844 | 33.5% |
| Unspecified | $2.0M | 262 | 19.9% |
| Consulting Fee | $1.7M | 491 | 16.8% |
| Food and Beverage | $1.6M | 65,216 | 15.9% |
| Travel and Lodging | $1.1M | 4,022 | 10.4% |
| Grant | $223,651 | 10 | 2.2% |
| Space rental or facility fees (teaching hospital only) | $125,911 | 58 | 1.2% |
| Education | $7,537 | 272 | 0.1% |
Payments by Type
General
$8.1M
71,913 transactions
Research
$2.0M
262 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| AMBER | $457,843 | 0 | 47 |
| IST 7: Rajagopalan (Univ Hosp Cleveland) | $200,628 | 0 | 1 |
| EMERALD | $200,387 | 0 | 37 |
| IST: Bansal - 12 months (Start date: August 2016) | $121,462 | 0 | 3 |
| RLY5016-401 | $119,348 | 0 | 29 |
| IST 5: Edwards (St. Louis University) | $117,217 | 0 | 4 |
| IST 3: Germain-Headley | $100,000 | 0 | 3 |
| Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Add-On (MAGMAAddOn) | $93,627 | 0 | 1 |
| IST 1: Mehta | $76,143 | 0 | 4 |
| HEOR (Intermountain Health Services CHYME Study) | $73,625 | 0 | 2 |
| Association of Potassium Levels with Mortality in Hospitalized Patients | $69,079 | 1 | 2 |
| Emerald | $67,118 | 0 | 74 |
| IST 4: Rafique | $51,149 | 0 | 3 |
| Amber | $48,518 | 0 | 38 |
| Frequency of Cardiac Arrhythmias in Dialysis Patients as a function of Hyperkalemia | $46,867 | 0 | 1 |
| Evaluation of Veltassa (patiromer) to maintain normokalemia in a patient population with chronic ki | $39,160 | 0 | 1 |
| Real World Effectiveness of Patiromer as an Adjunct Therapy in Acute Hyperkalemia | $30,525 | 0 | 2 |
| IST: Bansal - 12 months (Start date: August 2016) (PI MDM ID: 100032946) | $23,596 | 0 | 1 |
| Frequency of Cardiac Arrhythmias in Dialysis Patients as a | $23,443 | 0 | 1 |
| Pharmacokinetic Study of Tacrolimus and Mycophenolate Mofetil in Kidney | $22,458 | 0 | 1 |
| IST: Rogosin - Dr. Jun Lee | $22,458 | 0 | 1 |
| RLY5016-206p_IRB Fees_Site 1111_Butani_Corrected | $5,000 | 0 | 2 |
| Pharmacokinetic study of tacrolimus and mycophenolate mofetil in kidney transplant recipients | $3,430 | 0 | 2 |
| Comparison of Patiromer with Sodium Polystyrene (Kayexalate) in their ability | $2,000 | 0 | 1 |
| CHYME Study | $1,000 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 5
| Doctor | Specialty | Location | Total | 2020 |
|---|---|---|---|---|
| Dr. Padam Hirachan, Md, MD | Nephrology | Natchez, MS | $21,714 | $0 |
| Dr. Michelle Bloom, Md, MD | Cardiovascular Disease | Mineola, NY | $21,572 | $0 |
| Donald Hricik, Md, MD | Nephrology | Cleveland, OH | $21,404 | $0 |
| Unknown Provider | — | — | $21,038 | $0 |
| Amir Kaki, Md, MD | Interventional Cardiology | Detroit, MI | $20,573 | $0 |
| Dr. Barry Molk, M.d, M.D | Cardiovascular Disease | Lone Tree, CO | $20,257 | $0 |
| Joseph Roglieri, D.o, D.O | Nephrology | Troy, NY | $19,408 | $0 |
| Dr. Ana Stankovic, Md Facp Fasn Fash, MD FACP FASN FASH | Nephrology | Salem, NH | $18,725 | $0 |
| Prabir Roy-Chaudhury, M.d, M.D | Internal Medicine | Cincinnati, OH | $17,956 | $0 |
| Dr. Michael Brucculeri, M.d, M.D | Nephrology | Clearwater, FL | $17,106 | $0 |
| Kirkwood Adams, Md, MD | Cardiovascular Disease | Chapel Hill, NC | $16,675 | $0 |
| Unknown Provider | — | — | $16,546 | $0 |
| Ileana Pina, Md, Mph, MD, MPH | Cardiovascular Disease | Philadelphia, PA | $16,321 | $0 |
| David Pai, Md, MD | Specialist | Sacramento, CA | $16,048 | $0 |
| Robert Toto, Md, MD | Nephrology | Dallas, TX | $15,853 | $0 |
| Rajiv Agarwal, Md, MD | Cardiac Rehabilitation | Humble, TX | $15,598 | $0 |
| Ramachandra Malya, M. D, M. D | Internal Medicine | Houston, TX | $15,469 | $0 |
| Dr. William Yang, M.d, M.D | Nephrology | Northridge, CA | $15,336 | $0 |
| Dr. Mukesh Sinha, Md, MD | Specialist | Cypress, TX | $15,293 | $0 |
| William White, Md, MD | Hypertension Specialist | Farmington, CT | $14,841 | $0 |
| Charbel Salem, M.d, M.D | Nephrology | Ashland, KY | $14,765 | $0 |
| Dr. Varshasb Broumand, M.d, M.D | Internal Medicine | San Antonio, TX | $14,651 | $0 |
| Dr. Sitaramesh Emani, M.d, M.D | Clinical & Laboratory Immunology | Cincinnati, OH | $14,611 | $0 |
| William Peacock, Md, MD | Emergency Medicine | Houston, TX | $14,422 | $0 |
| Dr. George Kramer, M.d, M.D | Interventional Cardiology | Marietta, GA | $14,350 | $0 |
About Relypsa, Inc.
Relypsa, Inc. has made $10.1M in payments to 13,986 healthcare providers, recorded across 72,175 transactions in the CMS Open Payments database. In 2020, the company paid $980,819. The top product by payment volume is Veltassa ($8.2M).
Payments were distributed across 133 medical specialties. The top specialty by payment amount is Nephrology ($4.1M to 3,856 doctors).
Payment categories include: Food & Beverage ($1.6M), Consulting ($1.7M), Research ($2.0M), Travel & Lodging ($1.1M).
Relypsa, Inc. is associated with 1 products in the CMS Open Payments database.